News

Gilead Sciences announced that its Board of Directors has named Daniel O’Day Chairman of the Board and Chief Executive Officer, effective March 1, 2019. Mr. O’Day is currently the CEO…
Read More...

AstraZeneca announced a new collaboration with Cancer Research UK to launch a centre of excellence in genetic screening, cancer modelling and big data processing aimed at accelerating…
Read More...

Bristol-Myers Squibb Company and Vedanta Biosciences announced a clinical trial collaboration to evaluate Bristol-Myers Squibb's programmed death-1 (PD-1) immune checkpoint inhibitor…
Read More...

Pharmaceutical Product Development, LLC (PPD) is adding gene and cell therapy analytical testing to its GMP (good manufacturing practices) laboratory in Athlone, Ireland, to support the…
Read More...

Merck KGaA, Darmstadt, Germany announced that it has entered into a licensing agreement with Cyclica Inc. for the use of Ligand Express, a cloud-based in silico proteome screening…
Read More...

PAREXEL announced a new collaboration with Eli Lilly and Company to launch a clinical research learning and development program in China. The program will bring high-value training…
Read More...

Mylan announced the U.S. launch of Lansoprazole Delayed-Release (DR) Orally Disintegrating Tablets (ODT), 15 mg and 30 mg, a generic version of Takeda's Prevacid® SoluTab DR ODT. Mylan…
Read More...

Roche announced that the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq…
Read More...

AbbVie announced the decision to stop enrollment for the TAHOE trial, a Phase 3 study evaluating Rovalpituzumab Tesirine (Rova-T) as a second-line therapy for advanced small-cell lung…
Read More...

Icagen announced that they have entered into a license and collaboration agreement with Roche to develop and commercialize small molecule ion channel modulators for the treatment of…
Read More...

Momenta Pharmaceuticals, a biotechnology company with a validated scientific platform focused on discovering and developing novel therapeutics to treat rare, immune-mediated diseases,…
Read More...

Novartis announced the initiation of Phase III trials for ligelizumab (QGE031) - a high-affinity monoclonal anti-IgE antibody - in chronic spontaneous urticaria (CSU) patients whose…
Read More...

Evotec AG announced a new integrated drug discovery alliance with LEO Pharma, a global leader in medical dermatology. The collaboration goal is to generate new leads against innovative…
Read More...

Swedish life science company, OnDosis, and global contract development and manufacturing organisation (CDMO), Recipharm, have entered into an agreement for the formulation development…
Read More...

Changzhou Qianhong Bio-pharma Co., Ltd. started construction of the phase two of pharmaceuticals production facility at Changzhou National Hi-Tech District on November 28. With an…
Read More...

Pluristem Therapeutics announced that it has entered into a license agreement with a subsidiary of Chart Industries, Inc. regarding Pluristem’s thawing device for cell-based therapies.…
Read More...

Revance Therapeutics announced that the company has entered into a license agreement with Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd., (Fosun Pharma Industrial), a…
Read More...

Sartorius Stedim Biotech (SSB), a leading international supplier of the biopharmaceutical industry, through its China affiliate, and Beijing-based Immunochina Pharmaceuticals, announced…
Read More...

Scientist.com and Allele Biotechnology & Pharmaceuticals have partnered to develop nanoantibodies for therapeutic applications. Experts selected through Scientist.com’s Genius…
Read More...

Novartis announced that the U.S. Food and Drug Administration (FDA) has accepted the company's Biologics License Application (BLA) for AVXS-101, now known as ZOLGENSMA (onasemnogene…
Read More...